Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pfizer tests experimental pill to help older adults regain lost appetite

NCT ID NCT07086664

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called PF-07258669 in older adults (ages 60-89) who are at risk of malnutrition. The goal was to see if the drug is safe and how it affects the body. Participants took the drug or a placebo for 16 weeks. The study was terminated early, and only 7 people enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07258669 (oral tablet)
What this could lead to
If it works, this could point toward a treatment for unintended weight loss in older adults, helping improve appetite and nutrition.
What could go wrong
This is a very early, small Phase 1 trial in healthy volunteers, not patients. The study was terminated, so results may not be available. Safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

7 people

The number who actually took part.

Started

Aug 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 89 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Are 60 years to \<90 years Are males or females who can no longer have children Have Body weight ≥40 kg and Body mass index (BMI) ≤25 kg/m2 Exclusion Criteria Evidence or history of clinically significant medical conditions. Positive for active, untreated HIV, hepatitis B, and/or hepatitis C History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Voluntary diet restriction or eating disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers

Contacts and locations

Locations

  • AA Medical Research Center

    Flint, Michigan, 48504, United States

  • Accel Research Sites - Birmingham Clinical Research Unit

    Birmingham, Alabama, 35216, United States

  • Alpha Recherche Clinique

    Québec, Quebec, G3K 2P8, Canada

  • Bradenton Research Center, Inc.

    Bradenton, Florida, 34205, United States

  • Centre de Recherche Saint-Louis inc.

    Québec, G1W 4R4, Canada

  • Circuit Clinical

    Secaucus, New Jersey, 07094, United States

  • Circuit Clinical /North Hudson Community Action Corporation

    West New York, New Jersey, 07093, United States

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • De La Cruz Research Center, LLC

    Miami, Florida, 33184, United States

  • Diex Recherche Inc. Division Victoriaville

    Victoriaville, Quebec, G6P 3Z8, Canada

  • Headlands Research Orlando

    Orlando, Florida, 32819, United States

  • JEM Research Institute

    Atlantis, Florida, 33462, United States

  • Javara - Nevada Health Centers - Carson City

    Carson City, Nevada, 89706, United States

  • Yao Tokushukai General Hospital

    Yao Shi, Osaka, 581-0011, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.